The Challenge

Although immunotherapy has revolutionised cancer treatment, several challenges remain:

  • Many patients do not respond to, or become resistant to, immunotherapy
  • Some tumour types are non-responsive to immunotherapy (cold)
  • Efficacy can be limited by safety and toxicity

There is scope to increase the efficacy, applicability, and/or safety of existing immunotherapies.

Our mission is to develop novel, innovative and targeted medicines that augment endogenous anti-tumor immunity to improve outcomes for patients affected by cancer.